Results 161 to 170 of about 232,812 (303)
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon +2 more
wiley +1 more source
Reduced Pathogen-Specific T Cell Response With BCMA-Targeted T Cell-Engaging Therapy to Multiple Myeloma. [PDF]
Steiro I +9 more
europepmc +1 more source
While stakeholders saw value in cancer CQRs, concerns about funding, staffing, ethics, governance, and data quality were viewed as threats to sustainability. Ensuring ongoing value and viability will require investments in staff training and recruitment, integration with existing data collections, and clearer uses of CQR data to improve healthcare ...
Ashleigh R. Sharman +2 more
wiley +1 more source
Multiple Myeloma and Renal Health: Navigating Selected Clinical Complexities. [PDF]
Hussain A +3 more
europepmc +1 more source
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz +22 more
wiley +1 more source
Factors Affecting Prognosis in Patients with Extramedullary Myeloma: A Single-Center Experience. [PDF]
Bozan E +11 more
europepmc +1 more source

